BioSpace News Archive

One-year data from a Phase II study of Newron’s schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.

Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.

Moderna announced mixed interim results Thursday from a Phase III trial of mRNA seasonal flu vaccine candidate, mRNA-1010.

If Leqembi is granted priority review from the agency, full approval could come as soon as July, Ivan Cheung, chairman and CEO, Eisai Inc., told CNBC Thursday.

Abivax SA announced the appointment of Dr. Sheldon Sloan, M.D., M. Bioethics, as new Chief Medical Officer, effective on March 1, 2023.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

SciSparc Ltd. announced that its MitoCareX Bio Ltd. joint venture, which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions, has achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement with respect to MitoCare X Bio.

Scholar Rock announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 255,000 shares of common stock and inducement restricted stock units, covering an aggregate of 30,000 shares of its common stock.

Quantum-Si Incorporated, The Protein Sequencing CompanyTM, announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place, Boston, MA on March 6-8, 2023.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.